Preclinical activity of SHR-A1921, a novel antibody-drug conjugate targeting trophoblast cell-surface antigen2 (Trop-2) in prostate cancer

作者
Binyu Wang,Qiuya Xu,Shan Peng,Zheng Han,Haifeng Huang,Hongqian Guo,Xuefeng Qiu
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:17: 1713983-1713983
标识
DOI:10.3389/fphar.2026.1713983
摘要

Background Despite advances in the 5-year survival rates for prostate cancer patients, progression to metastatic castration-resistant prostate cancer (mCRPC) remains a significant challenge following standard treatments. Antibody-drug conjugates (ADCs) are an emerging class of biopharmaceuticals that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. Trophoblast cell surface antigen 2 (Trop-2) is overexpressed in prostate cancer, particularly in metastatic forms. Methods Response to this, we developed a novel Trop-2-targeted antibody-drug conjugate (ADC), SHR-A1921, which incorporates a potent DNA topoisomerase I inhibitor,SHR9265. Its in vitro cytotoxicity was assessed across prostate cancer cell lines with differential Trop-2 expression. Subcutaneous xenograft models were established for in vivo tumor-suppressive activity evaluation, and patient-derived organoid models validated its potential clinical efficacy. Results In preclinical models, SHR-A1921 specifically bound to Trop-2, followed by internalization into tumor cells and subsequent intracellular trafficking to lysosomes, where the release of SHR9265 occurred. This resulted in DNA damage and apoptosis in Trop-2-expressing tumor cells in vitro . In vivo , SHR-A1921 exhibited significant antitumor activity, inducing DNA damage in Trop-2-positive xenograft tumors. Additionally, SHR-A1921 demonstrated antitumor effects in Trop-2-expressing prostate cancer organoids. Safety assessments in rats indicated that SHR-A1921 had an acceptable safety profile. Conclusion SHR-A1921 is a promising Trop-2-targeted ADC that leverages innovative technology to deliver potent antitumor activity against Trop-2-expressing prostate cancer cells, with an acceptable safety profile observed in preclinical studies. These results highlight the promising clinical potential of SHR-A1921 as a therapeutic option for prostate cancer patients with Trop-2-positive tumors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yhuyfuhk完成签到 ,获得积分10
刚刚
呆萌发布了新的文献求助10
刚刚
田様的应助被Mxr采纳,获得10
1秒前
1秒前
董亦菲发布了新的文献求助10
1秒前
猫好好发布了新的文献求助10
1秒前
1秒前
1秒前
2秒前
Jevon完成签到 ,获得积分10
2秒前
2秒前
qiu发布了新的文献求助10
2秒前
2秒前
zisezhaoyan发布了新的文献求助10
2秒前
2秒前
华仔的应助被hhh采纳,获得10
3秒前
3秒前
汉堡包的应助被wsw111采纳,获得10
4秒前
4秒前
4秒前
呆萌完成签到,获得积分10
5秒前
搬砖ing完成签到,获得积分10
5秒前
molihuakai的应助被Lu采纳,获得10
5秒前
无极微光的应助被Shu采纳,获得30
5秒前
Amani_Nakupenda完成签到,获得积分10
5秒前
5秒前
6秒前
hahaha625的应助被古德采纳,获得10
6秒前
标致青雪发布了新的文献求助10
6秒前
lytelope完成签到,获得积分10
6秒前
6秒前
ZJH发布了新的文献求助10
7秒前
汉堡包的应助被杰里西采纳,获得10
7秒前
熊猫海发布了新的文献求助50
7秒前
7秒前
沙沙发布了新的文献求助10
7秒前
隐形曼青的应助被景麟采纳,获得10
7秒前
桐桐的应助被Stephen采纳,获得10
7秒前
gala的夏天发布了新的文献求助10
7秒前
织梦发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183091
求助须知:如何正确求助?哪些是违规求助? 9572406
关于积分的说明 21825003
捐赠科研通 7779812
什么是DOI,文献DOI怎么找? 3433837
关于科研通互助平台的介绍 2558045
邀请新用户注册赠送积分活动 2480046